Hhglim-M2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle cells. The combined action of these agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Hhglim-M2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to sulfonylurea activity. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Dose adjustments should be individualized based on glycemic response and tolerability. Hhglim-M2 Tablet PR should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.